- Home
- MBIO vs ALLR Comparison
MBIO vs ALLR Comparison
Compare MBIO & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBIO
- ALLR
- Stock Information
- Founded
- MBIO 2015
- ALLR 2004
- Country
- MBIO United States
- ALLR United States
- Employees
- MBIO N/A
- ALLR N/A
- Industry
- MBIO Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- MBIO Health Care
- ALLR Health Care
- Exchange
- MBIO Nasdaq
- ALLR Nasdaq
- Market Cap
- MBIO 7.3M
- ALLR 6.0M
- IPO Year
- MBIO N/A
- ALLR N/A
- Fundamental
- Price
- MBIO $3.63
- ALLR $1.03
- Analyst Decision
- MBIO Strong Buy
- ALLR
- Analyst Count
- MBIO 1
- ALLR 0
- Target Price
- MBIO $100.00
- ALLR N/A
- AVG Volume (30 Days)
- MBIO 416.1K
- ALLR 3.8M
- Earning Date
- MBIO 03-10-2025
- ALLR 03-07-2025
- Dividend Yield
- MBIO N/A
- ALLR N/A
- EPS Growth
- MBIO N/A
- ALLR N/A
- EPS
- MBIO N/A
- ALLR N/A
- Revenue
- MBIO N/A
- ALLR N/A
- Revenue This Year
- MBIO N/A
- ALLR N/A
- Revenue Next Year
- MBIO N/A
- ALLR N/A
- P/E Ratio
- MBIO N/A
- ALLR N/A
- Revenue Growth
- MBIO N/A
- ALLR N/A
- 52 Week Low
- MBIO $3.56
- ALLR $0.90
- 52 Week High
- MBIO $74.50
- ALLR $283.20
- Technical
- Relative Strength Index (RSI)
- MBIO 30.75
- ALLR 47.17
- Support Level
- MBIO $3.96
- ALLR $0.98
- Resistance Level
- MBIO $6.70
- ALLR $1.99
- Average True Range (ATR)
- MBIO 1.09
- ALLR 0.21
- MACD
- MBIO -0.12
- ALLR 0.00
- Stochastic Oscillator
- MBIO 1.69
- ALLR 15.45
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.